Author

Mary Chau

Observed name: M Chau

Institution: Enanta Pharmaceuticals (United States)

Observed institutions: University of Massachusetts Chan Medical School, Enanta Pharmaceuticals (United States)

OpenAlex ID: A5112435529

Characterization of EDP-305, a Highly Potent and Selective Farnesoid X Receptor Agonist, for the Treatment of Non-alcoholic Steatohepatitis

2019 · Mary Chau, Yang Li, et al. · International Journal of Gastroenterology · 16

A novel FXR agonist EDP-297 exerts anti-inflammatory and hepatoprotective effects in human liver 3D microtissues and rodent NASH and liver injury models

2020 · Mary Chau, Manuel Roqueta-Rivera, et al. · Journal of Hepatology · 1

EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model 2253997

2026 · Yaohui Nie, Manuel Roqueta-Rivera, et al. · The Journal of Immunology

Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases 2257118

2026 · Kelsey Garlick, Joyce Sweeney, et al. · The Journal of Immunology

C34-04 EPS-3903 is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in a House Dust Mite-Induced Asthma Mouse Model

2026 · Y Nie, M Roqueta-Rivera, et al. · American Journal of Respiratory and Critical Care Medicine

HSD17B13 inhibitors are hepatoprotective and anti-inflammatory in a mouse model of autoimmune hepatitis

2023 · Manuel Roqueta-Rivera, Yaohui Nie, et al. · Journal of Hepatology

Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury

2022 · Manuel Roqueta-Rivera, Mary Chau, et al. · Journal of Hepatology

FRI-340-In vivo effects of a novel inhibitor of apoptosis signal-regulating kinase 1 in mouse models of liver injury and metabolic disease

2019 · Manuel Roqueta-Rivera, Mary Chau, et al. · Journal of Hepatology

Su1502 - EDP-305, a Selective Farnesoid X Receptor Agonist, Exhibits Excellent Potency In Vitro and In Vivo and Anti-Fibrotic Effect In Vitro

2018 · Yang Li, Mary Chau, et al. · Gastroenterology

Su1498 - A Highly Selective and Potent Farnesoid X Receptor (FXR) Agonist EDP-305 Reduces Liver Steatosis, Ballooning, and Non-Alcoholic Fatty Liver Disease Activity (NAS) in two Murine Models of Non-Alcoholic Steatohepatitis (NASH)

2018 · Li-Juan Jiang, Mary Chau, et al. · Gastroenterology

Su1500 - EDP-305 Favorably Regulates Lipoprotein Mechanism In Vitro

2018 · Mary Chau, Manuel Roqueta-Rivera, et al. · Gastroenterology

A Novel Farnesoid X Receptor (FXR) Agonist, EDP-305, Reduces Fibrosis Progression in Animal Models of Hepatobiliary Injury

2017 · Derek J. Erstad, Christian T. Farrar, et al. · Gastroenterology

Diverse roles of Notch signaling in cardiac cell differentiation, migration and ventricular morphogenesis

2007 · Zheng-Zheng Bao, Mary Chau, et al. · Developmental Biology

WITHDRAWN: Diverse roles of Notch signaling in cardiac cell differentiation, migration and ventricular morphogenesis

2007 · Kevin Fogarty, Mary Chau, et al. · Developmental Biology

Works count: 14

Citation count: 17

H-index: 1

I10-index: 1